Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer

NCT06979908 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT06979908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06979908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 2
Overall status
Recruiting
Start date
January 22, 2025
Completion date
January 22, 2027
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer